We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...
GlobalData on MSN1d
Pfizer sets sights on Summit’s bispecific in combo with its ADCsPfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...
Summit Therapeutics sank -13.4% today, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...
Newsable Asianet News on MSN1d
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 LetdownSummit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...
Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial ...
Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback